GILEAD Sciences says it welcomes the Government's decision to fund Biktarvy on the Pharmaceutical Benefits Scheme (PBS) S100 (Community Access) from 01 Mar.
Biktarvy is a triple combination HIV therapy containing Descovy (emtricitabine and tenofovir alafenamide) with the novel INSTI, (bictegravir).
Visit tga.gov.au for the PI.
The above article was sent to subscribers in Pharmacy Daily's issue from 05 Mar 19
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 05 Mar 19
